Prostaglandin E1 synthesis pathway

The **Prostaglandin E1 synthesis pathway** refers to the series of biochemical reactions that produce prostaglandin E1 (PGE₁), a naturally occurring lipid mediator. This process begins with dihomo-gamma-linolenic acid, an omega‑6 fatty acid precursor, which is converted through enzymatic steps involving cyclooxygenase and specific prostaglandin synthases into PGE₁[2][6]. The main biological product—prostaglandin E₁—is a potent vasodilator that relaxes smooth muscle, inhibits platelet aggregation, and has various medical uses including maintaining ductus arteriosus patency in neonates with congenital heart defects and treating erectile dysfunction via its synthetic form alprostadil[2][3][4]. **Important note:** The "Prostaglandin E₁ synthesis pathway" is not itself a molecular target but rather describes an enzymatic process leading to production of a bioactive molecule. Therapeutic targets within this context are typically individual enzymes involved in biosynthesis—such as cyclooxygenase isoforms—or receptors activated by PGE₁. Drugs like alprostadil act as analogues/mimetics of PGE₁ rather than inhibitors/activators of its synthetic enzymes. If you require structured information about specific molecules within this pathway—such as "Cyclooxygenase 1," "Cyclooxygenase 2," or "Prostaglandin E synthase"—please specify which enzyme or receptor you wish to focus on. The entry “Prostaglandin E₁ synthesis pathway” is **not considered a canonical therapeutic target** but rather denotes a metabolic route; thus it should be flagged as incorrect if used where only discrete molecular targets are appropriate.[6][2]

Other names

PGE1 synthesisProstaglandin E1 biosynthesisPGE1 pathway